Obesity is a metabolic syndrome leading to several health problems such as hypertension,
heart attack, type II diabetes, and even cancer. Carbonic anhydrase VA (CAVA) is a mitochondrial enzyme
which is directly associated with the glucose homeostasis and considered as a promising target for
obesity and other associated diseases in humans. So far, numerous inhibitors have been designed to inhibit
the catalytic activity of CAVA with an assumption for its possible therapeutic uses against type II
diabetes and other metabolic diseases. Among these, sulphonamide inhibitors and various non-classical
inhibitors are extensively used. The focus of this review is to understand the mechanism and role CAVA
in glucose homeostasis to ascertain as a potential drug target of obesity. We have further highlighted
different types of inhibitors and their mode of binding and possible consequences with an aim to investigate
possible therapeutic used for the treatment of obesity and associated diseases. Along with classical
inhibitors, various non-classical inhibitors have proved to be potential inhibitors of CAV which may be
employed to combat obesity. Certain phytochemicals are utilized as therapeutic molecules to fight obesity.
These phytochemicals have been discussed in detail here.
Keywords: Carbonic anhydrase inhibitors, metabolic syndrome, sulphonamide inhibitors, obesity, drug design and discovery.
Rights & PermissionsPrintExport